Controversies in the pharmacological treatment of Graves’ disease in children

References

• Rivkees SA. Treatment of hyperthyroidism due to Graves’ disease in children. In Krassas GE, Rivkees SA, Kiess W, editors. Disease of the thyroid in childhood and adolescence. Pediatr Adolesc Med. Basel: Karger; 2007. Vol. 11, pp I-VIII (DOI:10.1159/000098003).
   Google Scholar
• Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–277.
   PubMed Web of Science ®Google Scholar
• Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128:230–234.
   PubMedGoogle Scholar
• Grüters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):S172–4.
   PubMed Web of Science ®Google Scholar
• Cappa M, Bizzarri C, Crea F. Autoimmune thyroid diseases in children. J Thyroid Res. 2011;675703. DOI:10.4061/2011/675703
   Google Scholar
• Wong GW, Lai J, Cheng PS. Growth in childhood thyrotoxicosis. Eur J Pediatr. 1999;158:776–779.
   PubMed Web of Science ®Google Scholar
• de Los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149:526–532.
   PubMedGoogle Scholar
• Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol. 2010;72:358–363.
   PubMed Web of Science ®Google Scholar
• Léger J. Graves’ disease in children. In Szinnai G editor. Paediatric thyroidology. Endocr Dev. Basel: Karger;2014. Vol. 26, p. 171–182.
   Google Scholar
• Forssberg M, Arvidsson CG, Engvall J, et al. Increasing incidence of childhood thyrotoxicosis in a population- based area of central Sweden. Acta Paediatr. 2004;93:25–29.
   PubMed Web of Science ®Google Scholar
• Havgaard Kjaer R, Smedegard Andersen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998–2012. Horm Res Paediatr. 2015;84:102–107.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Arrigo T, et al. Frequency of Hashimoto’s thyroiditis antecedents in the history of children and adolescents with graves’ disease. Horm Res Paediatr. 2010;73(6):473–476.
   PubMed Web of Science ®Google Scholar
• Aversa T, Lombardo F, Corrias A, et al. In young patients with Turner or Down syndrome, Graves’ disease presentation is often preceded by Hashimoto’s thyroiditis. Thyroid. 2014;24(4):744–747.
   PubMed Web of Science ®Google Scholar
• Williamson S, Greene SA. Incidence of thyrotoxicosis in the UK and Ireland. Clin Endocrinol. 2010;72:358–363.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015 Feb;14(2):174–180.
   PubMed Web of Science ®Google Scholar
• Brand OJ, Gough SC. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol. 2010;322:135–143.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Messina MF, et al. Graves’disease prevalence in a young population with Turner syndrome. J Endocrinol Invest. 2010;33:69–70.
   PubMed Web of Science ®Google Scholar
• Gawlik A, Gawlik T, Januszek-Trzciakowska A, et al. Incidence and dynamics of thyroid dysfunction and thyroid autoimmunity in girls with Turner’s syndrome: a long-term follow-up study. Horm Res Paediatr. 2011;76:314–320.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun. 2012;38:315–321.
   PubMed Web of Science ®Google Scholar
• Valenzise M, Aversa T, Corrias A, et al. Epidemiology, presentation and long-term evolution of Graves’ disease in children, adolescents and young adults with Turner syndrome. Horm Res Paediatr. 2014;81:245–250.
   PubMed Web of Science ®Google Scholar
• Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, et al. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol. 2009;71:110–114.
   PubMed Web of Science ®Google Scholar
• De Luca F, Corrias A, Salerno M, et al. Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol. 2010;162:591–595.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Sundquist J, et al. The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun. 2010;34:J307–13.
   PubMed Web of Science ®Google Scholar
• Ross DS, Burch HB, Cooper D, et al. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
   PubMed Web of Science ®Google Scholar
• Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol. 2006;155:783–786.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med. 2005;3:905–917.
   Web of Science ®Google Scholar
• Leger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab. 2018;32:373–386.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92:2157–2162.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360:1574–1575.
   PubMed Web of Science ®Google Scholar
• Balavoine AS, Glinoer D, Dubucquoi S, et al. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid. 2015;25:1273–1281.
   PubMed Web of Science ®Google Scholar
• Hallberg P, Eriksson N, Ibanez I, et al. Genetic variants associated with antithyroid drug induced agranulocytosis: a genome wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4:507–516.
   PubMed Web of Science ®Google Scholar
• Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93:3817–3826.
   PubMed Web of Science ®Google Scholar
• Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: aprospective, multi center study. Pediatrics. 2008;121:e481–e488.
   PubMed Web of Science ®Google Scholar
• Léger J, Gelwane G, Kaguelidou F, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97:110–119.
   PubMed Web of Science ®Google Scholar
• Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for Graves’ disease in children: along term retrospective study at single institution. Thyroid. 2014;24:200–207.
   PubMed Web of Science ®Google Scholar
• Gastaldi R, Poggi E, Mussa A, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014;164:1189–1194.e1.
   PubMed Web of Science ®Google Scholar
• Leger J, Kaguelidou F, Alberti C, et al. Graves’ disease in children. Best Pract Res Clin Endocrinol Metab. 2014;28:233–243.
   PubMed Web of Science ®Google Scholar
• Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves’disease: a review with emphasis on radioiodine treatment. Cleve Clin J Med. 1988;55:373–382.
   PubMed Web of Science ®Google Scholar
• Boice JD. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006;295:1060–1062.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–3776.
   PubMed Web of Science ®Google Scholar
• Metso S, Jaatinen P, Huhtala H, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–2196.
   PubMed Web of Science ®Google Scholar
• Ryodi E, Metso S, Jaatinen P, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidis. J Clin Endocrinol Metab. 2015;100:3710–3717.
   PubMed Web of Science ®Google Scholar
• Lal G, Ituarte P, Kebebew E, et al. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15:569–574.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–3065.
   PubMed Web of Science ®Google Scholar
• Breuer CK, Solomon D, Donovan P, et al. Effect of patient age on surgical outcomes for Graves’ disease: a case-control study of 100 consecutive patients at a high volume thyroid surgicalcenter. Int J Pediatr Endocrinol. 2013;1:1-9856–2013-1.
   Google Scholar
• Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr. 2010;74:305–311.
   PubMed Web of Science ®Google Scholar
• Burch HB, Burman KD, Cooper DSA. 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–4558.
   PubMed Web of Science ®Google Scholar
• Wong J, Wiseman SM. Thyroid surgery for treatment of Graves’ disease complicated by ophthalmopathy: a comprehensive review. Expert Rev Endocrinol Metab. 2015;10:327–336.
   PubMed Web of Science ®Google Scholar
• Aversa T, Crisafulli G, Zirilli G, et al. Epidemiological and clinical aspects of autoimmune thyroid diseases in children with Down’s syndrome. Ital J Pediatr. 2018;44:39.
   PubMed Web of Science ®Google Scholar
• Lauberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves’disease after therapy with anti-thyroid drugs, surgey or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69–75.
   PubMed Web of Science ®Google Scholar
• Luton D, Le Gac I, Vuillard E, et al. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab. 2005;90(11):6093–6098.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Nygaard B, Glinoer D, et al. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European thyroid association. Eur J Endocrinol. 1998;139:584–586.
   PubMed Web of Science ®Google Scholar
• Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves’ disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. 1983;57:1036–1040.
   PubMed Web of Science ®Google Scholar
• Banigé M, Polak M, Luton D. Research Group for Perinatal Dysthyroidism (RGPD) study group. prediction of neonatal hyperthyroidism. J Pediatr. 2018;197:249–254.e1.
   PubMed Web of Science ®Google Scholar
• Ferraris S, Valenzise M, Lerone M, et al. Malformations following methimazole exposure in utero: an open issue. Birth Defects Res A Clin Mol Teratol. 2003;67(12):989–992.
   PubMed Web of Science ®Google Scholar
• Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr. 2005;146:533–536.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Salerno M, et al. Outcomes of children with hashitoxicosis. Horm Res Paediatr. 2012;77(1):36–40.
   PubMed Web of Science ®Google Scholar